- Conditions
- Anterior Cruciate Ligament Reconstruction
- Interventions
- AirBand, uninflated AirBand
- Device
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Milford, Connecticut • North Haven, Connecticut
Location Directory
Clinical trials in New Haven, Connecticut
This page shows live ClinicalTrials.gov search results for New Haven, Connecticut, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
1349
Shown on this page
12
Current sort
Recently updated
Location scope
New Haven, CT
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 289–300 of 1,349 matching trials in New Haven, CT.
Live ClinicalTrials.gov results.
Institutions in New Haven
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Advanced Merkel Cell Carcinoma, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Metastatic Merkel Cell Carcinoma, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
- Interventions
- Pembrolizumab, Stereotactic Body Radiation Therapy
- Biological · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 254
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Fort Smith, Arkansas + 172 more
- Conditions
- Healthy Volunteer
- Interventions
- atirmociclib (PF-07220060)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Healthy Adult Participants
- Interventions
- PF-07248144, Itraconazole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Alcohol Consumption, Heavy Drinker, Alcohol Use Disorder (AUD)
- Interventions
- Mavoglurant
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 21 Years to 50 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut
- Conditions
- Prostate Cancer
- Interventions
- AMG 509, Abiraterone, Enzalutamide
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 479 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2032
- U.S. locations
- 25
- States / cities
- Duarte, California • Fullerton, California • San Francisco, California + 22 more
- Conditions
- Healthy Participant
- Interventions
- PF-08642534, Itraconazole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Chronic Pain, PERIPHERAL NEUROPATHY, Occipital Neuralgia, Chronic Hip Pain, Hip Osteoarthritis, Knee Osteoarthritis, Spasticity, Chronic Low Back Pain, Lumbar Spondylosis, Cervical Spondylosis, Shoulder Arthritis, Causalgia, Chronic Pain Syndrome, Chronic Neck Pain
- Interventions
- Not listed
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Old Saybrook, Connecticut
- Conditions
- Schizophrenia
- Interventions
- Emraclidine 30 mg
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 698 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 62
- States / cities
- Phoenix, Arizona • Bryant, Arkansas • Little Rock, Arkansas + 46 more
- Conditions
- Desmoid Tumor, Aggressive Fibromatosis
- Interventions
- Nirogacestat oral tablet, Placebo Oral Tablet
- Drug
- Lead sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 34
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 27 more
- Conditions
- Stroke, Stroke, Acute, Stroke, Ischemic
- Interventions
- Transcranial Magnetic Stimulation (TMS)
- Diagnostic Test
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 657 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 37 more
- Conditions
- AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar, NPM1 Mutation, MLL Rearrangement, Leukemia, Acute Myeloid Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Acute Leukemia, Neoplasms by Histologic Type
- Interventions
- Ziftomenib, Fludarabine, Idarubicin, Cytarabine, Gilteritinib, Granulocyte colony-stimulating factor
- Drug · Biological
- Lead sponsor
- Kura Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 38
- States / cities
- Gilbert, Arizona • Los Angeles, California • Orange, California + 32 more